Ocular Therapeutix Files 8-K on Operations and Financials
Ticker: OCUL · Form: 8-K · Filed: Aug 7, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations-update
Related Tickers: OCUL
TL;DR
OCUL filed an 8-K for financial updates, no specific numbers yet.
AI Summary
Ocular Therapeutix, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, and to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as an official update to the SEC regarding Ocular Therapeutix's financial status and operational results, providing transparency to investors.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of operational and financial information, not indicating any immediate adverse events.
Key Players & Entities
- OCULAR THERAPEUTIX, INC. (company) — Filer of the 8-K report
- August 7, 2024 (date) — Date of the earliest event reported
- 15 Crosby Drive Bedford, MA 01730 (location) — Principal Executive Offices address
- 001-36554 (company_id) — SEC File Number
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not include the specific financial figures or operational details within this excerpt.
When was this 8-K report filed with the SEC?
The report was filed on August 7, 2024.
What is the principal executive office address for Ocular Therapeutix, Inc.?
The principal executive offices are located at 15 Crosby Drive, Bedford, MA 01730.
What is the SEC file number for Ocular Therapeutix, Inc.?
The SEC file number is 001-36554.
What is the SIC code for Ocular Therapeutix, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-08-07 07:13:30
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq
Filing Documents
- tm2420962d1_8k.htm (8-K) — 25KB
- tm2420962d1_ex99-1.htm (EX-99.1) — 103KB
- 0001104659-24-086535.txt ( ) — 308KB
- ocul-20240807.xsd (EX-101.SCH) — 3KB
- ocul-20240807_lab.xml (EX-101.LAB) — 33KB
- ocul-20240807_pre.xml (EX-101.PRE) — 22KB
- tm2420962d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On August 7, 2024, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: 99.1 Press Release of Ocular Therapeutix, Inc., dated August 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: August 7, 2024 By: /s/ Donald Notman Donald Notman Chief Financial Officer